AUSTIN, Texas, Jan. 28, 2015
/CNW/ -- Luminex Corporation (NASDAQ: LMNX) announced it
has received a Health Canada Class 3 Device License approval for
its comprehensive genotyping assay, xTAG® CYP2D6 Kit v3.
Identification of patient CYP2D6 genotypes can help clinicians
individualize drug treatment by selecting appropriate
therapies.
Cytochrome P450 2D6 (CYP2D6) is a clinically important gene that
encodes a drug-metabolizing enzyme. CYP2D6 metabolizes greater than
25% of the drugs in use today including some cardiovascular and
anti-cancer drugs, anti-psychotics, anti-depressants,
pain-medications, beta blockers, and antiarrhythmics.
Variations in the CYP2D6 gene can result in distinct drug
metabolizing profiles leading to potentially sub-optimal drug
responses, such as drug toxicity, adverse drug reactions (ADRs), or
inadequate therapeutic effect. Approximately 1.6% of patients
admitted to acute care hospitals in Canada experience a serious adverse drug
reaction. With almost 2.5 million annual hospital admissions in
Canada of the type studied,
statistics suggest that an estimated 40,000 serious adverse drug
reactions occur annually in Canadian acute care
hospitals.1
xTAG CYP2D6 Kit v3 is an in vitro diagnostic assay that analyzes
a patient's CYP2D6 genotype from DNA extracted from a blood sample
and is used to aid physicians in determining therapeutic strategy
for drugs metabolized by the cytochrome P450 2D6 gene product. The
assay is run on the flexible Luminex® 100/200™ instrument. This new
version of the kit optimizes performance on the *17 allele and
features an updated software algorithm that detects all 17
genotypes that the assay is cleared for, including deletion and
duplication genotypes.
Additionally, another pharmacogenetic assay by Luminex, xTAG
CYP2C19 Kit v3, received Health Canada approval in 2014. The
CYP2C19 enzyme is responsible for metabolizing a variety of drugs
used to treat ulcers, seizures, malaria, anxiety, and some
antidepressants.
More information on Luminex's pharmacogenetic products, xTAG
CYP2D6 Kit v3 and xTAG CYP2C19 Kit v3, can be found at
www.luminexcorp.com/CYP2D6, www.luminexcorp.com/CYP2C19.
About Luminex Corporation
Luminex is committed to applying its passion for innovation
toward creating breakthrough solutions to improve health and
advance science. The company is transforming global healthcare and
life-science research through the development, manufacturing and
marketing of proprietary instruments and assays utilizing xMAP®
open-architecture multi-analyte
platform, MultiCode® real-time polymerase chain reaction
(PCR), and multiplex PCR-based technologies, that deliver
cost-effective rapid results to clinicians and
researchers. Luminex's technology is commercially available
worldwide and in use in leading clinical laboratories, as well as
major pharmaceutical, diagnostic, biotechnology and life-science
companies. Luminex is meeting the needs of customers in
markets as diverse as clinical diagnostics, pharmaceutical drug
discovery, biomedical research including genomic and proteomic
research, personalized medicine, biodefense research and food
safety. For further information on Luminex
Corporation and the latest advances in multiplexing using
award winning technology, please
visit http://www.luminexcorp.com/.
Sources:
1. Cadario B. New appreciation of serious adverse drug
reactions. BCMJ (Internet). Cited 2014 December. Available from:
http://www.bcmj.org/bc-centre-disease-control/new-appreciation-serious-adverse-drug-reactions.
Contacts
Luminex Corporate Contact:
Harriss Currie
Sr. Vice President, Finance and CFO
hcurrie@luminexcorp.com
512.219.8020
Luminex Media Contact:
Christine Valle
Sr. Manager, Global Marketing
cvalle@luminexcorp.com
512.219.8020
Photo -
http://mma.prnewswire.com/media/171774/luminex-corporation.jpg
Logo -
http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO
SOURCE Luminex Corporation